Evidence map›Paper›PMID 32024378›Full record

ArticleCell transplantation

Human Mesenchymal Stem Cells-mediated Transcriptomic Regulation of Leukemic Cells in Delivering Anti-tumorigenic Effects.

Vahid Hosseinpour Sarmadi, Salma Ahmadloo, Mohadese Hashem Boroojerdi, Cini Mathew John, Satar Jabbar Rahi Al-Graitte, Hamza Lawal, Maryam Maqbool, Ling King Hwa, Rajesh Ramasamy

Open access · goldAbstract read
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 4 countries.

Vahid Hosseinpour SarmadiDepartment of Pathology, Faculty of Medicine and Health Sciences, Stem Cell & Immunity Research Group, Immunology Laboratory, Universiti Putra Malaysia, Selangor, Malaysia.
Salma AhmadlooDepartment of Biomedical Science, Faculty of Medicine and Health Sciences, Genetics Laboratory, Universiti Putra Malaysia, Selangor, Malaysia.
Mohadese Hashem BoroojerdiDepartment of Pathology, Faculty of Medicine and Health Sciences, Stem Cell & Immunity Research Group, Immunology Laboratory, Universiti Putra Malaysia, Selangor, Malaysia.
Cini Mathew JohnDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Satar Jabbar Rahi Al-GraitteDepartment of Pathology, Faculty of Medicine and Health Sciences, Stem Cell & Immunity Research Group, Immunology Laboratory, Universiti Putra Malaysia, Selangor, Malaysia.
Hamza LawalDepartment of Pathology, Faculty of Medicine and Health Sciences, Stem Cell & Immunity Research Group, Immunology Laboratory, Universiti Putra Malaysia, Selangor, Malaysia.
Maryam MaqboolDepartment of Pathology, Faculty of Medicine and Health Sciences, Stem Cell & Immunity Research Group, Immunology Laboratory, Universiti Putra Malaysia, Selangor, Malaysia.
Ling King HwaMedical Genetics Laboratory, Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.
Rajesh RamasamyDepartment of Pathology, Faculty of Medicine and Health Sciences, Stem Cell & Immunity Research Group, Immunology Laboratory, Universiti Putra Malaysia, Selangor, Malaysia.ORCID 0000-0003-4227-0458
Universiti Putra Malaysia · MYUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of leukemia has become much difficult because of resistance to the existing anticancer therapies. This has thus expedited the search for alternativ therapies, and one of these is the exploitation of mesenchymal stem cells (MSCs) towards control of tumor cells. The present study investigated the effect of human umbilical cord-derived MSCs (UC-MSCs) on the proliferation of leukemic cells and gauged the transcriptomic modulation and the signaling pathways potentially affected by UC-MSCs. The inhibition of growth of leukemic tumor cell lines was assessed by proliferation assays, apoptosis and cell cycle analysis. BV173 and HL-60 cells were further analyzed using microarray gene expression profiling. The microarray results were validated by RT-qPCR and western blot assay for the corresponding expression of genes and proteins. The UC-MSCs attenuated leukemic cell viability and proliferation in a dose-dependent manner without inducing apoptosis. Cell cycle analysis revealed that the growth of tumor cells was arrested at the G

Indexed as

ApoptosisCell CycleCell Line, TumorCell ProliferationGene Expression ProfilingGene OntologyHL-60 CellsHumansLeukemiaMesenchymal Stem CellsReverse Transcriptase Polymerase Chain ReactionUmbilical Cordcell cyclegene expression profilingleukemiamesenchymal stem cells

Identifiers

PMID32024378
PMCPMC7444238
OpenAlexW3005052456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.